Efficacy and safety of Stereotactic Radiosurgery (SRS) in the management of brain metastases in patients with metastatic melanoma.
OBJECTIVES We sought to identify factors associated with prognosis and bleeding in patients with melanoma brain metastases(BM).Objectives were median overall survival (mOS [months]) and bleeding incidence. METHODS We conducted a retrospective analysis of patients receiving SRS at our center 11/1511/23.Analysis was performed on Prism 10.1.1.Extraction from electronic medical records was undertaken by authors, with local R&D approval(NEU012). RESULTS 81 patients were evaluable. 119 treatment courses were delivered. There were no bleeding events (BE) in the first 7 days , 1 within 28 days(0.8%) and 19 within 90 days(16%).7.6%(N = 9) died within 90 days and 25.2%(N = 30) died within 6 m. There were no deaths within 30 days or related to treatment.mOS was 17.6 m(95% CI 9.20-35.05).Significantly inferior survival outcomes were observed for patients with elevated lactate dehydrogenase(LDH),poor performance status(Karnofsky performance status [KPS]),higher total treated intracranial volume(GTV) and total number of BM.mOS of patients with a normal LDH was 37.0 m vs 5.2 m for those with LDH >ULN(HR 4.40, P<.0001).This was also true on multivariable analysis including KPS, BM number and BM size(HR 3.75 95%CI 1.94-7.30, p = <0.0001).For patients with KPS ≥90 mOS was 35.0 m vs 7.7 m for KPS ≤80(HR 2.55, P<.0004).This was significant using the multivariable analysis described above(HR 2.12 95%CI 1.123-3.948, p = 0.0181). CONCLUSIONS Despite theoretically high risk of bleeding after SRS in MM BM, incidence of bleeding in our cohort was low.mOS was comparable to historical controls of 16-23 months. ADVANCES IN KNOWLEDGE We novelly performed univariate and multivariate analysis demonstrating poor survival outcomes in patients with high LDH, poor performance status and larger brain metastases (both by BM size and number).